2026-04-29T17:03:12Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/226142024-11-28T21:48:54Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud
author
Perello, Joan
author
Gomez, M
author
Ferrer, MD
author
Rodriguez, NY
author
Salcedo, C
author
Buades-Fuster, Juan Manuel
author
Perez, MM
author
Torregrosa, JV
author
Martin, E
author
Maduell, F
2024-09-06T09:56:41Z
2024-09-06T09:56:41Z
2018-04
Perello Bestard J, Gomez M, Ferrer MD, Rodriguez NY, Salcedo C, Buades-Reine'S JM, et al. SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels. J Nephrol. 2018 Apr;31(2):287-96. Epub 2018 Jan 19.
10.1007/s40620-018-0471-9
1724-6059
1121-8428
Journal of Nephrology
http://hdl.handle.net/20.500.13003/9373
29350348
L620281026
2-s2.0-85040706941
https://hdl.handle.net/20.500.12105/22614
426358000014
Background: Cardiovascular calcification (CVC) is a major concern in hemodialysis (HD) and the loss of endogenous modulators of calcification seems involved in the process. Phytate is an endogenous crystallization inhibitor and its low molecular mass and high water solubility make it potentially dialyzable. SNF472 (the hexasodium salt of phytate) is being developed for the treatment of calciphylaxis and CVC in HD patients. We aimed to verify if phytate is lost during dialysis, and evaluate SNF472's behaviour during dialysis. Methods: Dialyzability was assessed in vitro using online-hemodiafiltration and high-flux HD systems in blood and saline. SNF472 was infused for 20 min and quantified at different time points. Results Phytate completely dialyzed in 1 h at low concentrations (10 mg/l) but not when added at 30 or 66.67 mg/l SNF472. In bypass conditions, calcium was slightly chelated during SNF472 infusion but when the system was switched to dialysis mode the calcium in the bath compensated this chelation. Conclusion: Phytate dialyses with a low clearance. The administration of SNF472 as an exogenous source of phytate allows to attain supra-physiological levels required for its potential therapeutic properties. As SNF472 is infused during the whole dialysis session, the low clearance would not affect the drug's systemic exposure.
eng
Cardiovascular calcification
End-stage renal disease
Hemodialysis
Phytate
SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels
research article